Bi-shRNAfurin and GMCSF augmented autologous tumour cell immunotherapy - Gradalis/Mary Crowley Cancer Research Center
Alternative Names: bi-shRNA(furin)/GMCSF DNA/autologous tumor cell vaccine; Bi-shRNAfurin; FANG™; Vigil™Latest Information Update: 25 Sep 2023
At a glance
- Originator Gradalis; Mary Crowley Cancer Research Center
- Developer Genentech; Gradalis; Mary Crowley Cancer Research Center
- Class Antineoplastics; Cancer vaccines; Cell therapies; Gene therapies; Immunotherapies; RNA; Tumour cell vaccines
- Mechanism of Action Furin expression inhibitors; Granulocyte-macrophage colony-stimulating factor expression stimulants; Immunostimulants; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Ewing's sarcoma
- Phase II Breast cancer; Cervical cancer; Endometrial cancer; Fallopian tube cancer; Gynaecological cancer; Ovarian cancer; Peritoneal cancer; Uterine cancer
- No development reported Cancer; Colorectal cancer; Lung cancer; Solid tumours
- Discontinued Liver metastases; Malignant melanoma
Most Recent Events
- 22 Sep 2023 Gradalis plans a phase II trial in Ovarian cancer (Recurrent) .
- 21 Dec 2022 US FDA gives clearance for registrational phase III VITAL-V trial in Ovarian cancer
- 21 Dec 2022 Gradalis plans a phase III trial in Ovarian cancer (Late-stage disease and Newly diagnosed) in USA in 2H of 2023 (Intradermal)